Login to Your Account

Benitec dropping HCV program, citing competition

By Michael Fitzhugh
Staff Writer

Friday, February 26, 2016

Benitec Biopharma Ltd. is winding down its lead program, the HCV candidate TT-034, terminating further development of the phase I/IIa drug. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription